Abstract
The present review summarizes the available information on the effects of the three major classes of antianginal agents (nitrates, calcium and beta-blockers) on myocardial energy metabolism. It also discusses the role of some new molecules (L-carnitine, trimetazidine and ranolazine) that have been proposed as an alternative pharmacological approach for the metabolic management of cardiac ischaemic syndromes.
MeSH terms
-
Acetanilides
-
Adrenergic beta-Antagonists / therapeutic use*
-
Angina Pectoris / drug therapy*
-
Calcium Channel Blockers / therapeutic use*
-
Carnitine / therapeutic use
-
Energy Metabolism / drug effects
-
Humans
-
Myocardium / metabolism*
-
Nitroglycerin / therapeutic use*
-
Piperazines / therapeutic use
-
Ranolazine
-
Trimetazidine / therapeutic use
Substances
-
Acetanilides
-
Adrenergic beta-Antagonists
-
Calcium Channel Blockers
-
Piperazines
-
Ranolazine
-
Nitroglycerin
-
Trimetazidine
-
Carnitine